close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OSE Immunotherapeutics

< Previous 1 2 Next >
News headline image
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
Appointment of Marc Le Bozec as Interim CEO
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
Update on Information Relating to the General Meeting of September 30, 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Publishes Letter to Shareholders
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics provides an update on ongoing proceedings
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
From OSE Immunotherapeutics
Via GlobeNewswire
News headline image
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
From OSE Immunotherapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today